For research teamsHelp me find a study
Back to all studies
TerminatedNCT04825860

SEP 363856 for schizophrenia

This study was terminated in China, in Japan, in the Philippines, .... It is testing SEP 363856 for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether SEP-363856 may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive SEP-363856, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in China, in Japan, and in the Philippines.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: March 29, 2021
Recruitment status
Terminated
Enrollment listed in the registry
83
Sponsor
Sumitomo Pharma Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
China, Japan, Philippines, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT04825860
Official title
A Randomized, Double-blind, Parallel-group, Placebo Controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in Acutely Psychotic Patients With Schizophrenia, Followed by an Open-label Extension Phase

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT04825860. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

China · 8 sites
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing Municipality
    Site status: Not listed — confirm with the team
  • Peking University Sixth Hospital
    Beijing, Beijing Municipality
    Site status: Not listed — confirm with the team
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong
    Site status: Not listed — confirm with the team
  • The Second People's Hospital of Hunan Province/ Brain Hospital of Hunan Province
    Changsha, Hu'nan
    Site status: Not listed — confirm with the team
  • Shandong Daizhuang Hospital
    Jining, Shandong
    Site status: Not listed — confirm with the team
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality
    Site status: Not listed — confirm with the team
  • The Mental Health Center of Xi'an
    Xian, Shanxi
    Site status: Not listed — confirm with the team
  • Tianjin Anding Hospital
    Tianjin, Tianjin Municipality
    Site status: Not listed — confirm with the team
Japan · 38 sites
  • Hotei Hospital
    Kōnan, Aichi-ken
    Site status: Not listed — confirm with the team
  • Okehazama Hospital Fujita Kokoro Care Center
    Toyoake, Aichi-ken
    Site status: Not listed — confirm with the team
  • Medical corporation Seijinkai Seinan Hospital
    Hachinohe, Aomori
    Site status: Not listed — confirm with the team
  • Kohnodai Hp., National Center for Global Health and Medicine
    Ichikawa, Chiba
    Site status: Not listed — confirm with the team
  • Shiranui Hospital
    Omuta, Fukuoka
    Site status: Not listed — confirm with the team
  • Juzenkai Oorin Hospital
    Ōnojō, Fukuoka
    Site status: Not listed — confirm with the team
  • Takeda General Hospital
    Aizu-Wakamatsu, Fukushima
    Site status: Not listed — confirm with the team
  • Mihara Hospital
    Mihara, Hiroshima
    Site status: Not listed — confirm with the team
  • Fujimidai Hospital
    Hiratsuka, Kanagawa
    Site status: Not listed — confirm with the team
  • Okinawa Tokushukai Hino Hospital
    Yokohama, Kanagawa
    Site status: Not listed — confirm with the team
  • Yatsushiro Kosei Hospital
    Yatsushiro, Kumamoto
    Site status: Not listed — confirm with the team
  • Miyakonojo Shinsei Hospital
    Miyakonojō, Miyazaki
    Site status: Not listed — confirm with the team
  • Shonan Hospital
    Matsumoto, Nagano
    Site status: Not listed — confirm with the team
  • Mental Support Soyokaze Hospital
    Ueda, Nagano
    Site status: Not listed — confirm with the team
  • NHO Ryukyu Hospital
    Kunigami, Okinawa
    Site status: Not listed — confirm with the team
  • Social welfare corporation Tenshinkai Kosaka hospital
    Higashiosaka, Osaka
    Site status: Not listed — confirm with the team
  • Kansai Medical University Medical Center
    Moriguchi, Osaka
    Site status: Not listed — confirm with the team
  • Nishiurakai Keihan Hospital
    Moriguchi, Osaka
    Site status: Not listed — confirm with the team
  • Neyagawa Sanatorium
    Neyagawa, Osaka
    Site status: Not listed — confirm with the team
  • Asakayama Hospital
    Sakai, Osaka
    Site status: Not listed — confirm with the team
  • Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital
    Takatsuki, Osaka
    Site status: Not listed — confirm with the team
  • NHO Hizen Psychiatric Center
    Kanzaki, Saga-ken
    Site status: Not listed — confirm with the team
  • Rainbow & Sea Hospital
    Karatsu, Saga-ken
    Site status: Not listed — confirm with the team
  • Nishi Kumagaya Hospital
    Kumagaya, Saitama
    Site status: Not listed — confirm with the team
  • Shiga university of medical science hospital
    Ōtsu, Shiga
    Site status: Not listed — confirm with the team
  • Negishi Hospital
    Fuchū, Tokyo
    Site status: Not listed — confirm with the team
  • National Center of Neurology and Psychiatry
    Kodaira, Tokyo
    Site status: Not listed — confirm with the team
  • Narimasu Kosei Hospital
    tabashi City, Tokyo
    Site status: Not listed — confirm with the team
  • National Hospital Organization Hokuriku National Hospital
    Nanto, Toyama
    Site status: Not listed — confirm with the team
  • Azusakai Kawada Hospital
    Takaoka, Toyama
    Site status: Not listed — confirm with the team
  • Sanyokai Sanyo Hospital
    Sakata, Yamagata
    Site status: Not listed — confirm with the team
  • Akino Hospital
    Tendō, Yamagata
    Site status: Not listed — confirm with the team
  • Akita City Hospital
    Akita
    Site status: Not listed — confirm with the team
  • Inokuchi Noma Hospital
    Fukuoka
    Site status: Not listed — confirm with the team
  • Kuramitsu Hospital
    Fukuoka
    Site status: Not listed — confirm with the team
  • Minkodo Aburayama Hospital
    Fukuoka
    Site status: Not listed — confirm with the team
  • Satokai Yuge Hospital
    Kumamoto
    Site status: Not listed — confirm with the team
  • Miyazaki Prefectural Miyazaki Hospital
    Miyazaki
    Site status: Not listed — confirm with the team
Philippines · 5 sites
  • Mariveles Mental Wellness and General Hospital
    Mariveles, Bataan
    Site status: Not listed — confirm with the team
  • St. Paul's Hospital of Iloilo, Inc.
    Iloilo City, Iloilo
    Site status: Not listed — confirm with the team
  • Makati Medical Center
    Makati City, National Capital Region
    Site status: Not listed — confirm with the team
  • National Center for Mental Health
    Mandaluyong, National Capital Region
    Site status: Not listed — confirm with the team
  • Southern Philippines Medical Center
    Davao City
    Site status: Not listed — confirm with the team
Taiwan · 3 sites
  • Chang Gung Memorial Hospital, Keelung
    Keelung
    Site status: Not listed — confirm with the team
  • National Taiwan University Hospital
    Taipei
    Site status: Not listed — confirm with the team
  • Taipei Veterans General Hospital
    Taipei
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving SEP-363856 50 mg, SEP-363856 75 mg, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Sumitomo Pharma Co., Ltd., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.